ArticleInvestigative ophthalmology & visual science2025
Novel Visceral Obesity Indicators and Associated Metabolic Fingerprint in Incident Diabetic Retinopathy.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Body Roundness Index and Reported Vision Difficulty in U.S. Children and Adolescents: A Cross-Sectional Study of NHANES 2021-2023.Healthcare (Basel, Switzerland) · 2026Article
- Systemic metabolic dysfunction is associated with local treatment failure: the role of visceral adiposity index in anti-VEGF resistance in diabetic macular edema.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Evidence on the association between visceral obesity and diabetic retinopathy (DR) remains sparse and debatable. We aimed to use three novel indicators, body roundness index (BRI), lipid accumulation product (LAP), and visceral adiposity index (VAI), to investigate the longitudinal relationship between visceral obesity and DR, and explore the potential metabolic mechanisms. Methods: In this prospective study based on the UK Biobank (UKB), 14,738 individuals with diabetes free of DR at baseline were included. Cox proportional hazards regression models were adopted to explore the association among the three indices and DR. Based on nuclear magnetic resonance (NMR) metabolomics of 168 plasma metabolites, we performed elastic net regression to select metabolites associated with visceral obesity and DR. Enrichment and pathway analyses were used to investigate biological pathways and network analysis was performed to discover the metabolic interactions. Results: Over a 10-year follow-up, 1594 subjects developed DR. In the fully adjusted models, the three indices were significantly correlated with a high risk of DR, especially in Caucasians. Furthermore, we identified a metabolic fingerprint comprising 12 biomarkers associated with visceral obesity and DR, including 3-hydroxybutyrate, acetone, alanine, albumin, citrate, intermediate-density lipoprotein particles, creatinine, glucose, glycine, glycoprotein acetyls, pyruvate, and tyrosine. These metabolites were mainly enriched in alanine metabolism and their interaction was partly through succinic acid. Conclusions: Visceral obesity indices (BRI, LAP, and VAI) were positively associated with DR onset in patients with DM, and the potential mechanism involves alanine and energy metabolism. Our findings may promote early detection and precision prevention of DR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.